| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0208571AFR2841900B1 (en) | 2002-07-08 | 2002-07-08 | NOVEL SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES |
| Publication Number | Publication Date |
|---|---|
| ZA200501082Btrue ZA200501082B (en) | 2007-01-31 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200501082AZA200501082B (en) | 2002-07-08 | 2005-02-07 | Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof |
| Country | Link |
|---|---|
| US (3) | US7943661B2 (en) |
| EP (1) | EP1525177B1 (en) |
| JP (1) | JP4575771B2 (en) |
| KR (1) | KR100974577B1 (en) |
| CN (1) | CN100548960C (en) |
| AT (1) | ATE365703T1 (en) |
| AU (1) | AU2003264698B2 (en) |
| BR (1) | BRPI0312398B8 (en) |
| CA (1) | CA2490986C (en) |
| CY (1) | CY1108085T1 (en) |
| DE (1) | DE60314633T2 (en) |
| DK (1) | DK1525177T3 (en) |
| EA (1) | EA011090B1 (en) |
| ES (1) | ES2287528T3 (en) |
| FR (1) | FR2841900B1 (en) |
| IL (2) | IL165696A0 (en) |
| MX (1) | MXPA05000427A (en) |
| NO (1) | NO329700B1 (en) |
| NZ (1) | NZ538051A (en) |
| PL (1) | PL207362B1 (en) |
| PT (1) | PT1525177E (en) |
| SI (1) | SI1525177T1 (en) |
| WO (1) | WO2004005233A1 (en) |
| ZA (1) | ZA200501082B (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2841784B1 (en) | 2002-07-08 | 2007-03-02 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2EN-1-ONE DERIVATIVES, PREPARATION AND USES | |
| FR2841900B1 (en) | 2002-07-08 | 2007-03-02 | Genfit S A | NOVEL SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES |
| EA011305B1 (en)* | 2004-01-08 | 2009-02-27 | Жанфит | 1,3-diphenylprop-2-en-10one derivative compounds, preparation method thereof and uses of same |
| FR2902789A1 (en) | 2006-06-21 | 2007-12-28 | Genfit Sa | SUBSTITUTED 1,3-DIPHENYLPROPANE DERIVATIVES, PREPARATIONS AND USES |
| US20100285126A1 (en)* | 2007-08-02 | 2010-11-11 | Rahul Dabre | Pharmaceutical compositions of fenofibrate |
| US10722575B2 (en) | 2009-11-26 | 2020-07-28 | Genfit | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders |
| DK2641596T3 (en)* | 2009-11-26 | 2018-08-06 | Genfit | Use of 1,3-diphenylprop-2-en-1-one derivatives for the treatment of liver disorders |
| US9221751B2 (en) | 2009-11-26 | 2015-12-29 | Genfit | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders |
| WO2011080276A1 (en) | 2009-12-29 | 2011-07-07 | Genfit | Pharmaceutical combinations comprising a dpp-4 inhibitor and a 1,3-diphenylprop-2-en-1-one derivative |
| CN103025703B (en)* | 2010-05-17 | 2015-10-14 | 金菲特公司 | The improvement preparation of chalcone derivative |
| TWI415600B (en)* | 2011-08-10 | 2013-11-21 | Univ Kaohsiung Medical | Composition for treating atherosclerosis and a preparation method thereof |
| WO2013098374A1 (en) | 2011-12-28 | 2013-07-04 | Genfit | 1,3-diphenylpropane derivatives, preparations and uses thereof |
| CN102697757B (en)* | 2012-05-18 | 2014-06-04 | 广州军区广州总医院 | Application of p-hydroxy benzylidene acetone in preparation of drugs for preventing and/or treating encephalopathy |
| HUE042569T2 (en)* | 2013-01-18 | 2019-07-29 | Genfit | Methods of treatment of fibrosis and cancers |
| EP3416629A4 (en)* | 2016-02-16 | 2019-08-07 | CoNCERT Pharmaceuticals, Inc. | Deuterated gft-505 |
| CA3018132C (en)* | 2016-03-31 | 2024-02-13 | Genfit | Use of elafibranor in the treatment of a cholestatic disease |
| FR3056909B1 (en)* | 2016-09-30 | 2019-04-19 | Nashpharm | COMPOSITION COMPRISING AT LEAST ONE PHARMACEUTICALLY ACCEPTABLE SALT OF SOLUBLE ELAFIBRANOR IN AQUEOUS MEDIA HAVING IMPROVED INTESTINAL ABSORPTION |
| FR3056908B1 (en) | 2016-09-30 | 2019-04-19 | Nashpharm | METFORMIN AND ELAFIBRANOR SALT HAVING DUAL ACTIVITY FOR THE TREATMENT OF OBESITY ASSOCIATED WITH NON-ALCOHOLIC STEATO-HEPATITIS (NASH) AND HYPERTRIGLYCERIDEMIA |
| CA3047098A1 (en)* | 2016-12-16 | 2018-06-21 | Jia Zhou | Inhibitors of bromodomain-containing protein 4 (brd4) |
| CN110312705B (en)* | 2017-01-22 | 2021-07-09 | 苏州科睿思制药有限公司 | Crystal form of GFT-505, preparation method and application thereof |
| EP3585374B1 (en) | 2017-02-21 | 2023-07-19 | Genfit | Combination of a ppar agonist with a fxr agonist |
| EP3585384A1 (en) | 2017-02-24 | 2020-01-01 | Genfit | Pharmaceutical compositions for combination therapy |
| WO2018193007A1 (en) | 2017-04-18 | 2018-10-25 | Genfit | Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor |
| CN108658908B (en)* | 2017-07-31 | 2019-05-10 | 广州必贝特医药技术有限公司 | 1,3- bis- replaces ketene compounds and its application |
| EP3661914A1 (en) | 2017-08-04 | 2020-06-10 | Advitech Advisory and Technologies SA | Process for the preparation of elafibranor and novel synthesis intermediates |
| WO2019053582A1 (en) | 2017-09-13 | 2019-03-21 | Novartis Ag | Combinations comprising fxr agonists |
| WO2019099761A1 (en) | 2017-11-16 | 2019-05-23 | Teva Pharmaceuticals International Gmbh | Solid state forms of elafibranor |
| JP7259850B2 (en) | 2017-11-30 | 2023-04-18 | シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド | Aromatic compounds, pharmaceutical compositions and uses thereof |
| EP3514541A1 (en) | 2018-01-17 | 2019-07-24 | Siemens Healthcare Diagnostics Products GmbH | Method of quantitative determination of a therapeutical tnf-alpha inhibitor |
| WO2019186410A1 (en)* | 2018-03-27 | 2019-10-03 | Lupin Limited | Solid forms of elafibranor and processes thereof |
| WO2020025789A1 (en) | 2018-08-03 | 2020-02-06 | Genfit | Elafibranor salts |
| WO2020039297A1 (en)* | 2018-08-24 | 2020-02-27 | Mankind Pharma Ltd. | Novel compounds and their use in preparation of elafibranor and pharmaceutical acceptable salts thereof |
| WO2020115628A1 (en)* | 2018-12-03 | 2020-06-11 | Mankind Pharma Ltd. | Solid forms of elafibranor and process of preparation thereof |
| CN110156648A (en)* | 2019-05-30 | 2019-08-23 | 河北科技大学 | A kind of preparation method of Elafibranor intermediate |
| EP3996698A1 (en)* | 2019-07-09 | 2022-05-18 | DSM IP Assets B.V. | Reducing the viral activity of elafibranor with riboflavin or dha |
| CN114630660A (en) | 2019-10-28 | 2022-06-14 | 基恩菲特公司 | Combination therapy with antioxidant properties |
| WO2021098885A1 (en)* | 2019-11-21 | 2021-05-27 | 杭州百诚医药科技股份有限公司 | α-FLUOROCHALCONE DERIVATIVES AND APPLICATION THEREOF |
| CN111138264B (en)* | 2019-11-29 | 2023-08-04 | 温州医科大学 | Syringaldehyde derivative and application thereof in preparing anti-gynecological tumor drugs |
| CN113121394B (en)* | 2019-12-30 | 2022-11-08 | 中国药科大学 | Preparation method of phenoxyacetic acid derivative |
| JP2023513712A (en) | 2020-02-10 | 2023-04-03 | ジェンフィット | Polymorphs of Elafibranol |
| CN114901641B (en)* | 2020-02-28 | 2025-06-17 | 四川科伦博泰生物医药股份有限公司 | Aromatic compounds and pharmaceutical compositions and uses thereof |
| KR20230011958A (en) | 2020-05-18 | 2023-01-25 | 장피트 | Elafibranor for the treatment of primary sclerosing cholangitis |
| IL299970A (en) | 2020-08-26 | 2023-03-01 | Genfit | Compositions and methods for the treatment of primary biliary cholangitis |
| CN113230240B (en)* | 2021-03-22 | 2022-12-27 | 广州医科大学 | 1,3-Diphenylprop-2-en-1-one derivatives and their applications |
| CN114853686B (en) | 2021-08-23 | 2023-06-20 | 中国药科大学 | Triazolone compounds and their medicinal uses |
| CN115894379B (en) | 2022-01-20 | 2025-06-27 | 哈尔滨三联药业股份有限公司 | Hydantoin compound and medical application thereof |
| WO2024184365A1 (en) | 2023-03-06 | 2024-09-12 | Genfit | Solid dosage forms of elafibranor |
| WO2025040345A1 (en) | 2023-08-22 | 2025-02-27 | Ipsen Pharma | Elafibranor for use in the treatment of primary biliary cholangitis |
| CN118363355B (en)* | 2024-06-19 | 2024-08-30 | 武汉名实生物医药科技有限责任公司 | Real-time monitoring system for product production |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3558612A (en) | 1968-05-22 | 1971-01-26 | Dow Chemical Co | Substituted phenoxyacetic acids |
| CH593224A5 (en)* | 1973-10-30 | 1977-11-30 | Taisho Pharmaceutical Co Ltd | |
| US3994955A (en)* | 1975-01-20 | 1976-11-30 | G. D. Searle & Co. | Substituted phenoxydialkylacetic acids and esters |
| JPS5278856A (en) | 1975-12-26 | 1977-07-02 | Taisho Pharmaceut Co Ltd | Preparation of chalcone ethers |
| US4190671A (en)* | 1977-03-17 | 1980-02-26 | Biorex Laboratories Limited | Chalcone derivatives |
| JPS5419947A (en) | 1977-07-16 | 1979-02-15 | Taisho Pharmaceut Co Ltd | Chalcone derivatives |
| GB8426424D0 (en)* | 1984-10-19 | 1984-11-28 | Biorex Laboratories Ltd | Chalcone derivatives |
| JPS6310720A (en) | 1986-07-01 | 1988-01-18 | Nippon Kayaku Co Ltd | 5-lipoxygenase inhibitor and anti-allergic agent |
| JPH023670A (en)* | 1988-06-22 | 1990-01-09 | Nippon Oil & Fats Co Ltd | Alkylthiochalcone derivative |
| EP0399051B1 (en) | 1988-11-25 | 1994-05-11 | Dainippon Ink And Chemicals, Inc. | Polyvalent antiinflammatory agent |
| JPH0442229A (en)* | 1990-06-08 | 1992-02-12 | Fujitsu Ltd | Resist material and pattern formation method |
| JPH05255655A (en) | 1992-03-12 | 1993-10-05 | Kanebo Ltd | UV absorber |
| JPH06122623A (en) | 1992-10-09 | 1994-05-06 | Minofuaagen Seiyaku Honpo:Goushi | Antitumor agent |
| US5276058A (en)* | 1993-06-09 | 1994-01-04 | Nippon Hypox Laboratories Incorporated | 3,4-dihydroxychalcone derivatives |
| DE4327365A1 (en)* | 1993-08-14 | 1995-02-16 | Boehringer Mannheim Gmbh | Use of phenols and phenol derivatives as drugs with a fibrinogen-lowering effect |
| US5523302A (en) | 1993-11-24 | 1996-06-04 | The Du Pont Merck Pharmaceutical Company | Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists |
| AU5474198A (en) | 1996-12-24 | 1998-07-17 | National Research Council Of Canada | Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals |
| EP0947511A1 (en) | 1998-03-30 | 1999-10-06 | F. Hoffmann-La Roche Ag | Derivatives of phenoxy acetic acid and of phenoxymethyl tetrazole having antitumor activity |
| WO2000023073A1 (en) | 1998-10-20 | 2000-04-27 | Korea Institute Of Science And Technology | Bioflavonoids as plasma high density lipoprotein level increasing agent |
| EP1254658B1 (en)* | 2000-01-27 | 2008-09-24 | Takara Bio Inc. | Remedies for the treatment of nerve diorders |
| US6608101B1 (en) | 2000-06-20 | 2003-08-19 | Atherogenics, Inc. | 1, 3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders |
| EP1254759B1 (en) | 2001-05-03 | 2009-03-18 | Leister Process Technologies | Nozzle for welding plastic webs or films |
| FR2841900B1 (en) | 2002-07-08 | 2007-03-02 | Genfit S A | NOVEL SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES |
| FR2841784B1 (en) | 2002-07-08 | 2007-03-02 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2EN-1-ONE DERIVATIVES, PREPARATION AND USES | |
| FR2857361B1 (en) | 2003-07-08 | 2005-09-09 | Genfit S A | PREPARATION OF 1,3-DIPHENYPROP-2-¼n-1-one DERIVATIVES |
| EA011305B1 (en)* | 2004-01-08 | 2009-02-27 | Жанфит | 1,3-diphenylprop-2-en-10one derivative compounds, preparation method thereof and uses of same |
| Publication | Publication Date | Title |
|---|---|---|
| ZA200501082B (en) | Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof | |
| IL165977A (en) | Substituted pyrimidinylaminobenzamides , process for the preparation thereof and pharmaceutical compositions comprising the same | |
| MY125978A (en) | Admantane derivatives | |
| AU2003233010A8 (en) | Process for the preparation of 3,3,4,4-tetrafluoropyrrolidine and derivatives thereof | |
| WO2004006858A3 (en) | Compounds, compositions, and methods employing same | |
| GR990100140A (en) | Novel compounds | |
| WO2002072022A3 (en) | Substituted tetracycline compounds as antifungal agents | |
| IL162669A0 (en) | Antichlinergic agents, method for producing the same and use thereof as medicaments | |
| AU2003297199A8 (en) | Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof | |
| IL161428A0 (en) | Oligoamine derivatives, methods for the production thereof and pharmaceutical compositions containing the same | |
| WO2002067865A3 (en) | N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof | |
| ZA200309514B (en) | Pyrido-pyrido-pyrrolo pyrrolo-indole and pyrido-pyrrolo pyrrolo carbazole derivatives, method for the production thereof and pharmaceutical compositions containing said derivatives. | |
| GR20020100478A (en) | Anhydrous crystalline valaciclivier hydrochloride | |
| AU2002368133A1 (en) | 1,3-azole derivative and medicinal composition containing the derivative for treatment for thombosis | |
| IL164887A0 (en) | Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith | |
| CA2296560A1 (en) | Amino acid derivatives useful to treat stroke | |
| MXPA03006249A (en) | 2-arylimino-2,3-dihydrothiazole derivatives, methods for preparing them and therapeutic use thereof. | |
| AU6814701A (en) | Methods and compositions for producing a neurosalutary effect in a subject | |
| AU2003232108A8 (en) | 1,1- and 1,2-bisphosphonates as apoliprotein e modulators | |
| PL369632A1 (en) | Novel 5-thio-ss-d-xylopyranoside derivatives, preparation method thereof, pharmaceutical compositions containing same and the therapeutic use thereof | |
| MXPA04005226A (en) | 1,3-diarylprop-2-en-1-ones, compositions containing same and use thereof. | |
| HUP0103686A2 (en) | Use of rolipram, ariflo or diazepino-indole, triazolo-quinazoline derivatives for the preparation of pharmaceutical compositions preventing or treating diseases associated with an excess in il-12 production | |
| AU2002311623A1 (en) | Process for the preparation of 1,4-dihydropyridines and novel 1,4-dihydropyridines useful as therapeutic agents | |
| AU2003249999A8 (en) | 1,4,7,10-tetraazacyclododecanes as modulators of the guanine-binding protein for treating tumours | |
| EP1515960A4 (en) | 2-thioxothiazole derivative, method for preparing the same, and pharmaceutical composition containing the same |